Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...

(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the potential for ...

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL ...

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

The FDA approved a 900-unit insulin glargine pen, the highest capacity long-acting insulin pen on the market in the U.S., Sanofi announced in a press release. The new insulin glargine (Toujeo) Max ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

TRENTON, N.J. (AP) - A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit ...